to treat both joint pain and cognitive impairment in rheumatoid arthritis published Sept 29, 2022

keepontruckin

Senior Member
Messages
178
Likes
446
https://www.sciencedaily.com/releases/2022/09/220929133330.htm

Scientists have now examined the role of monoamine oxidase-B (MAO-B) in RA. MAO-B and related molecules were upregulated in patients' joints and the brain.
MAOs, including MAO-A and MAO-B, are enzymes that catalyze the oxidation of monoamines and are bound to the outer mitochondrial membrane in cells of several organs, such as the brain and the immune system. More than 30 years ago, previous research suggested that MAO inhibitors can relieve pain and stiffness in RA patients. However, there have been no follow-up studies of these results, and further studies related to the role of MAO in RA have been generally lacking even until today.

Taken together, this study revealed both joint inflammation and cognitive impairment have a common underlying mechanism in RA patients, namely aberrant MAO-B expression. This opens the possibility of treating both of these symptoms with one drug.
"The mechanism by which cognitive impairment in RA is induced by reactive astrocytes caused by chronic inflammation was first presented. It is hoped that the newly developed and improved MAO-B inhibitor KDS2010 will become an effective next-generation treatment for RA," explains Director C. Justin LEE, who supervised this work.